VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC

Heather A. Wakelee, MD, Stanford University, Stanford, CA, talks on the findings of IMpower010, a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Adjuvant immune checkpoint blockade demonstrated disease-free survival (DFS) benefit with a safety profile consistent of atezolizumab monotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Heather A. Wakelee, MD has received research funding from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Merck, Novartis, Pharmacyclics, Sea Gen, Xcovery; is on the advisory board (compensated) of AstraZeneca, Xcovery, Janssen, Daiichi Sankyo, Blueprint, Mirati, Helsinn; is on the advisory board (not compensated) of Merck Genentech/Roche; the president elect at IASLC; part of the executive committee at ECOG-ACRIN.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter